Good MorningEquities pulled back again on Tuesday following another round of hotter than expected inflation data. The PPI came in at 0.8% for the month, up 0.2% from October and 0.3% hotter than forecast. The figure is coupled with high core readings and the hottest YOY increases on record.
If there was any doubt the FOMC would be raising interest rates sooner than expected this news should lay those doubts to rest. The CME Fedwatch tool is pricing in a near 60% chance the first hike will come by May and a 70% chance for two .25% interest rate hikes by June so today’s FOMC meeting is more important than ever. The Fed is expected to accelerate the taper and move the timeline for rate hikes forward.
Featured: Sell these "safe" blue chips immediately (Ad) 
|
Markets | |
When you have a precise retirement savings number you'd like to achieve, it takes dedication and consistent investing to get there.
Luckily, Americans have confidence that they'll achieve their retirement goals. Three in four workers (73%) believe they can fully retire with a comfortable lifestyl... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Consumer Discretionary | | Casino operator Las Vegas Sands (NYSE: LVS) stock has fallen down to its COVID-19 low levels in recent weeks. The epicenter stock has seen renewed fears of China intervention with the Macau gambling industry as well as COVID-19 protocols tightening again. Gambling is one of the few industries that d... Read the Full Story |
|
Consumer Discretionary | |
Since the early days of the pandemic, the reopening trade has been a popular way play the anticipated turnaround in beaten up, economically sensitive stocks.
Some groups like restaurants and retailers have recovered much if not all of their 2020 losses. Others like airlines and hotels have many m... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Technology | |
Just when many companies began anticipating welcoming employees back to the office, the Omicron variant has caused some to reconsider. Google (NASDAQ:GOOGL) and Ford (NYSE:F) are two examples of companies that just announced they are delaying their return-to-work plans.
But the repercussions of... Read the Full Story |
|
Healthcare | |
3 Low-Volatility Stocks Showing Strength in a Weak Market
Market sentiment can change in the blink of an eye, and that’s quite evident in the recent selling pressure we’ve seen occurring in the high growth areas. A lot of this likely has to do with the upcoming Federal Reserve meeting... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Discretionary | |
Rivian or Lucid Motors, Both Look Good For the Long Haul, Which is Best Right Now?
Electric vehicle (EV) stocks remain one of the most intriguing plays for investors. After a sharp sell-off earlier this year, stocks of EV companies are beginning to reinflate. And two of the hottest stocks in the ... Read the Full Story |
|
Markets | |
It’s Time To Get Ready For Q4 2021 Earnings
With the S&P 500 (NYSEARCA: SPY) Q4 earnings cycle having already started, it is time to get ready for the peak of the season. The peak is still quite a few weeks away but it pays to be ready. So far, reports from names like Oracle (NYSE: ORCL... Read the Full Story |
|
Markets | | Fiber optics providers Ciena (NYSE: CIEN) and Clearfield (NASDAQ: CLFD) are trading at multi-year highs as network upgrades spur revenue growth.
Although they operate in similar industries and are well established, these are quite different companies.
With a market capitalization of $11.49 billi... Read the Full Story |
|
Consumer Discretionary | |
Winnebago Is A Buy Before Earnings
To answer the question, are insiders buying Winnebago (NYSE: WGO) ahead of earnings, we must say yes, they are, or at least one did. Director Maria Favlana Blase bought 364 shares for a grand total of $24,053 at the end of October capping off a year in which mo... Read the Full Story |
|
Markets | |
Hexo Hits New Low In Wake Of Q1 Earnings
Hexo (NYSE: HEXO) reported its Q1 earnings and provided a forecast for profitability that has shares of the stock on the move. The caveat is that shares are moving lower right now and are just off the new low set in the wake of the report. As good as the ... Read the Full Story |
|
The Early Bird Stock Of The Day Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. | | View Today's Stock Pick |
|
